Skip to main content
Signal8

Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa

$ZURAPress releaseNov 9, 2026, 7:00 AM ETRead the release

Zura Bio's Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in hidradenitis suppurativa missed its primary endpoint, with AN-count reductions of 56.0% (300 mg) and 58.1% (150 mg) versus 52.5% on placebo; HiSCR50 and HiSCR75 secondary endpoints were also not met. Zura is discontinuing development of tibulizumab in HS, but will continue the ongoing TibuSURE trial in systemic sclerosis (data H1 2027) and the planned NEXUS-PMR study in polymyalgia rheumatica (data Q4 2028).

Key figures

Drug Name
tibulizumab (ZB-106)
Phase Of Trial
Phase 2
Cash runway
sufficient through at least end of 2028
Hiscr50 150mg
52.7%
Hiscr50 300mg
48.0%
Hiscr75 150mg
34.0%
Hiscr75 300mg
35.3%
Hiscr50 placebo
45.5%
Hiscr75 placebo
28.1%
Cash and equivalents
187700000
Enrolled participants
247
An count reduction 150mg
58.1%
An count reduction 300mg
56.0%
An count reduction placebo
52.5%

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.